» Articles » PMID: 33842403

Promotion of Cervical Screening Among Long-term Non-attendees by Human Papillomavirus Self-sampling

Overview
Journal J Cancer Prev
Specialty Oncology
Date 2021 Apr 12
PMID 33842403
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer is preventable through gynecological screening. To promote participation among non-attending women, self-collected vaginal samples for detection of high-risk human papillomavirus (hr-HPV) is an option. The aims of this study were to investigate the response of self-collected vaginal samples for hr-HPV testing among long-term non-attendees, to explore the attendance at follow-up among HPV-positive women, and to analyze the prevalence of hr-HPV and severe cervical dysplasia or cancer among the responders. A vaginal self-sampling kit was sent to 19,766 women aged 30-70 years who had not provided a cervical screening sample for ≥ 7 years in Skåne, Sweden. The self-sample was analyzed by the Aptima HPV mRNA assay (Hologic). Women testing positive for HPV were invited for follow-up. The response was 18.5% (3,646/19,757). The prevalence of HPV mRNA was 11.3% (412/3,636). Among HPV-positive women, 85.7% (353/412) attended follow-up, and of these, 44.8% (158/353) had HPV in the cervical sample. The HPV mRNA test of self-samples showed a positive predictive value of 9.3% ([33/353], 95% CI = 6.5-12.9) for detection of cytologically severe dysplasia. Histologically severe dysplasia or cancer was detected in 0.88% ([32/3,636], 95% CI = 0.6-1.2) among responders, including two cervical- and one vaginal cancer. In conclusion, almost one fifth of the long-term non-attendees participated in self-collected vaginal hr-HPV sampling. The prevalence of histologically confirmed high grade squamous intraepithelial lesion or cervical cancer was not increased significantly compared to regularly screened women in Sweden. The relatively high HPV prevalence among the self-samples indicates the importance of diagnostic follow-up with cervical HPV testing and reflex-cytology of HPV-positive cases.

Citing Articles

Human papillomavirus genotype and cycle threshold value from self-samples and risk of high-grade cervical lesions: A post hoc analysis of a modified stepped-wedge implementation feasibility trial.

Lei J, Cuschieri K, Patel H, Lawrence A, Deats K, Sasieni P PLoS Med. 2024; 21(12):e1004494.

PMID: 39666756 PMC: 11637256. DOI: 10.1371/journal.pmed.1004494.


Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations.

Zigras T, Mayrand M, Bouchard C, Salvador S, Eiriksson L, Almadin C Curr Oncol. 2023; 30(6):5652-5679.

PMID: 37366908 PMC: 10297596. DOI: 10.3390/curroncol30060425.


Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial.

Winer R, Lin J, Tiro J, Miglioretti D, Beatty T, Gao H JAMA Netw Open. 2022; 5(11):e2244343.

PMID: 36449291 PMC: 9713609. DOI: 10.1001/jamanetworkopen.2022.44343.


Human papillomavirus self-sampling with mRNA testing benefits routine screening.

Auvinen E, Nieminen P, Pellinen J, Dillner J, Tarkkanen J, Virtanen A Int J Cancer. 2022; 151(11):1989-1996.

PMID: 35716139 PMC: 9796070. DOI: 10.1002/ijc.34170.

References
1.
Broberg G, Gyrd-Hansen D, Jonasson J, Ryd M, Holtenman M, Milsom I . Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2013; 134(9):2223-30. DOI: 10.1002/ijc.28545. View

2.
Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Strand A, Sanner K . Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology. Br J Cancer. 2018; 118(6):896-904. PMC: 5886121. DOI: 10.1038/bjc.2017.485. View

3.
Darlin L, Borgfeldt C, Forslund O, Henic E, Hortlund M, Dillner J . Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J Clin Virol. 2013; 58(1):155-60. DOI: 10.1016/j.jcv.2013.06.029. View

4.
Ernstson A, Urdell A, Forslund O, Borgfeldt C . Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection. Infect Agent Cancer. 2020; 15:10. PMC: 7017526. DOI: 10.1186/s13027-020-00280-0. View

5.
Bulkmans N, Berkhof J, Bulk S, Bleeker M, van Kemenade F, Rozendaal L . High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer. 2007; 96(9):1419-24. PMC: 2360183. DOI: 10.1038/sj.bjc.6603653. View